Loading menu...

Prostate Cancer (PCa) will affect most men if they live long enough and PCa is one of the leading causes of cancer deaths.

 
Each year over 200,000 men are newly diagnosed with PCa in North America.  CPC-100 is for asympto-matic 'watchfull waiting' PCa patients who fail prostate removal & hormone therapy, with no approved drug availble to them. 

Drugs for  therapy-resitant solid cancers & hypoxic conditions 

 Colby's mission is to develop & sell drugs for hypoxia & therapy-resistant tumors

Colby drugs resore therapy-sensitivity or normoxia

Colby Pharmaceutical Company has developed  new therapeutic drugs  for treating prostate and other hypoxic and therapy-resistant solid tumors. read more »

 

Colby drugs treat therapy resistance & hypoxia.

Colby has developed  new  signal transduction, oxidative-stress  and hypoxia inhibitor drugs for treatment of prostate and other solid tumors which restore normoxia and therapy-sensitivity.
 
Colby demonstrated restoration of therapy-sensitivity for prostate  and other recurrent solid tumors with drug therapies that enable significantly longer survival time in animal models.  read more »
 

The Technology Platform enables pharmaceuticals as well as companion diagnostics restoring therapy-sensitivity & normoxia in patients.

Colby has identified  signaling pathways in hypoxia & therapy-resistant conditions. read more»
 

Disclaimer and Forward-Looking Statements

This web site contains "forward-looking statements," including statements about the Company's growth, future operating results, discovery and development of products, strategic alliances and intellectual property.Forward-looking statements include statements concerning our plans, objectives, goals, strategies, future events, future revenues or performance, capital expenditures, compensation arrangements, financing needs, plans or intentions relating to acquisitions, business trends and other information that is not historical information. Various important risks may cause the Company's actual results to differ materially from the results indicated by these forward-looking statements, including: adverse results in its drug discovery, pre-clinical and clinical development programs; failure to obtain grants; failure to obtain patent protection for its discoveries; commercial limitations imposed by patents owned or controlled by third parties; difficulties or delays in obtaining regulatory approvals to market products and services resulting from the Company's development efforts; product withdrawals; competitive factors; difficulties or delays in commercialization of Company's products; and the requirement for substantial funding to conduct research and development and to expand commercialization activities.

 

Highlights


  • Colby Pharmaceutical Company Corporate Presentation- update in progress

  •  

Recent Events- update in progress

 
 

read more >>

   

Meet Colby Executives-update in progress